1 / 39

Anesthesia for Supratentorial Tumors

Anesthesia for Supratentorial Tumors. Pekka O. Talke, MD Department of Anesthesia and Neurosurgery, Cottrell Chief of Neuroanesthesia University of California, San Francisco. Title. 35.000 brain tumors/yr 85% primary 60% primary and supratentorial 15% mets (1/6 of tumors).

evelyn
Download Presentation

Anesthesia for Supratentorial Tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Anesthesia for Supratentorial Tumors • Pekka O. Talke, MD • Department of Anesthesia and • Neurosurgery, Cottrell • Chief of Neuroanesthesia • University of California, San Francisco

  2. Title • 35.000 brain tumors/yr • 85% primary • 60% primary and supratentorial • 15% mets (1/6 of tumors)

  3. General Considerations • Surgical exposure (retraction) • Intracranial pressure (ICP) • Secondary insult to brain • Hemorrhage, seizures, air emboli • Rapid emergence • Stress response

  4. ICP • Tissue, blood, CSF • Intracranial-Volume relationship • Effects of anesthetics on ICP • Tumor mass and edema (steroids)

  5. Anesthetics • Intravenous anesthetics (not ketamine) are cerebral vasoconstrictors • Reduce CMR • CO2 reactivity intact

  6. Anesthetics cont. • Volatile anesthetics are cerebral vasodilators • Increase ICP • Reduce CMR • CO2 reactivity intact

  7. Anesthetics cont. • Nitrous oxide increases CMR and ICP • Can be controlled by hypocapnia • Opioids reduce CMR • CO2 reactivity intact • Nitroglycerine, nitroprusside, hydralazine are cerebral vasodilators

  8. Reduction of ICP • Intravenous anesthetics • Hyperventilation (30-35 mmHg) • Mannitol (0.5-1.0 gm/kg, 320 mOsm/kg), (hypernatremia, hypokalemia, hypovolemia) hypertonic saline • Lasix • CSF drainage • Hypoxia, hypovolemia • Head position (venous drainage) • Increase MAP

  9. Preop Plan • Vascular access • Fluid therapy • Anesthetics • Ventilation • Monitoring • Neuromonitoring

  10. Preop • Sedation=hypercapnia, hypoxia, obstruction • Stress: increased CMR, CBF • Analgesia/sedation midas 0.5.-2.0 mg/fentanyl (25- 100 ug) • Steroids • Anticonvulsants (relaxants, loading SLOW)

  11. Preop cont. • Two large Ivs • A-line (CPP, ABG, glucose, osm) • Asleep? To avoid stress

  12. Monitoring • BP, HR, CVP? • Pulse ox • ERTCo2 • Temperature (hypothermia?) • Urine • Relaxometry (hemiplegia, dilantin, tegretol) • Glucose, Hg, Hct

  13. Monitoring cont. • EEG • SSEP • ICP? • Motor mapping

  14. Induction • Avoid hypoxia, hypercarbia, stress response • Propofol/pentothal/hyperventilate • Opioids/relaxants • Head position (venous obstruction) • More drugs for intubation/pinning

  15. Maintenance • Control CMR, CBF • Good depth of anesthesia • Adequate CPP

  16. Maintenance cont. • Volatile (<1 MAC)/intravenous anesthetics/N2O • Mild hyperventilation • Aim for speedy emergence (CT scan)

  17. Increased ICP • Hyperventilate • Venous drainage • Relaxation • Change to IV anesthesia • Delete N2O • Diuretics

  18. Fluids • Not hypoosmolar • Colloids (bleeding) • Mannitol (320 mOsm/g)

  19. Emergence • Attenuate stress response (autoregulation impaired/labetalol) • Avoid hypercarbia, hypoxia (opioids) • Avoid coughing • Slow awakening (CT) • Seizure, edema, hematoma, pheumocephalus, vessel occlusion, ischemia, metabolic

  20. Title

  21. Title

  22. Title

  23. Intracranial • Increased intracranial pressure • Midline shift: tearing of the cerebral vessels • Herniation: falx, transtentorial, trans-foramen • Magnum, transcraniotomy • Epilepsy • Vasospasm

  24. Systemic • Hypercapnia • Hypoxemia • Hypotension or hypertension • Hypoosmolality or hyperosmolality • Hypoglycemia • Hyperglycemia • Shivering or pyrexia • Low cardiac output

  25. Prevention • No overhydration • Sedation, analgesia, anxiolysis • No noxious stimulus applied without sedation and Local Anesthesia • Head-up position, no compression of the jugular veins, head straight • Osmotic agents: mannitol, hypertonic saline

  26. Prevention cont. • Beta-blockers or clonidine or lidocaine • Steroids, if a tumor is present • Adequate hemodynamics: MAP, CVP, PCWP, HR • Adequate ventilation: Paco2>100 mm Hg, Paco2 35 mm Hg • Intrathoracic pressure as low as possible • Hyperventilation on demand before induction • Use of intravenous anesthetic agents for induction and maintenance in case of tensed brain

  27. Treatment • CSF drainage if ventricular or lumbar catheter in situ • Osmotic agents • Hyperventilation • Augmentation of anesthesia with intravenous anesthetic agents: propofol, thiopentone, etomidate • Muscle relaxant • Venous drainage: head up no PEEP, reduction of inspiratory time • Mild controlled hypertension if autoregulation present

  28. History • Seizure • Increased intracranial pressure (ICP): headache, nausea, vomiting, blurred vision • Decreased level of consciousness, somnolence • Focal neurologic signs: hemiparesis, sensory deficits, cranial nerve deficits, and so on • Paraneoplastic syndromes including presence of thrombosis

  29. Physical Evaluation • Mental status • Papilledema (increased ICP) • Signs of Cushing’s response: hypertensive bradycardia • Pupil size, speech deficit, Glasgow coma score, focal signs • Medication • Steroids • Antiepileptic drugs

  30. Technical Examination (CT or MRI Scan) • Size and location of the tumor: silent or eloquent area, near a major vessel, and so on • Intracranial mass effect: midline shift, decreased size of the ventricles, temporal lobe hernia • Intracranial mass effect: hydrocephalus, cerebrospinal fluid space around brainstem • Others: edema, brainstem involvement, pneumocephalus (recraniotomy)

  31. Evaluation of Hydration Status • Duration of bed rest • Fluid intake • Diuretics • Inappropriate secretion of antidiuretic hormone

  32. Induction • Adequate anxiolysis in the anesthetic room • Adequate fluid loading (5 to 7 ml/kg of NaCl 0.9%) • ECG leads in place; capnometer, pulse oximeter, and noninvasive blood pressure monitors • Insertion of intravenous and arterial lines under local anesthesia • Fentanyl 1 to 2 g/kg or alfentanil, sufentanil, or remifentanil

  33. Induction cont. • Preoxygenation and voluntary hyperventilation • Propofol 1.25 to 2.5 mg/kg or thiopentone 3 to 6 mg/kg for induction • Nondepolarizing muscle relaxant: vecuronium, rocuronium, or other controlled ventilation at Paco2 of 35 mm Hg • Propofol 50 to 150 g /kg/min or isoflurance 0.5% to 1.5% (or sevoflurane of desflurane) for maintenance and fentanyl (or alfentanil, sufentanil, or remifentanil) 1 to 2 g/kg or alfentanil, sufentanil, or remifentanil

  34. Induction cont. • Lignocaine 1.5 mg/kg • Intubation • Local anesthesia and intravenous fentanyl 2 g/kg for skull-pin head-holder placement and skin incision adequate head-up positioning; no compression of the jugular veins • Mannitol 0.5 to 0.75 g/kg • Insertion of a lumbar drain • Possibly N2O when the dura is open and brain is slack • Normovolemia with the use of NaCl 0.9% or starch 6%—no Ringer’s lactate

  35. ICP Control • Mild hyperosmolality (use NaCl 0.9% [304 mOsm/kg] • as baseline infusion; give mannitol [1319 mOsm/kg] • 0.5 to 0.75 g/kg or hypertonic saline [7.5% 2533 mOsm/kg] 3 to 5 ml/kg before bone flap removal) • Intravenous anesthetic agent (propofol), adequate depth of anesthesia • Mild hyperventilation, mild hyperoxygenation

  36. ICP Control cont. • Mild controlled hypertension: MAP maintained around 100 mm Hg in order to decrease CBV and ICP • Normovolemia; no vasodilators • Mild hyperoxia • Together with: • Adequate head-up positioning • Free venous drainage; no compression of the jugular veins • No PEEP, no ventilator fight (myorelaxants) • Lumbar drainage • Avoidance of brain retractors

  37. Awakening • Neurosurgical awakening should maintain: • Stable arterial blood pressure and thus cerebral blood flow and intracranial pressure • Stable oxygenation and carbon dioxide tension • Stable CMRO2 • Normothermia

  38. Awakening cont. • Neurosurgical awakening should avoid: • Coughing • Tracheal suctioning • Airway overpressure during extubation • Patient-ventilator dyssynchrony

  39. Awakening cont. • Neurosurgical awakening should provide: • Optimal conditions for neurologic examination

More Related